Trexquant Investment LP Grows Position in Kura Oncology, Inc. $KURA

Key Points

• Trexquant Investment LP increased its holdings in Kura Oncology by 21% in Q1, owning 685,970 shares valued at approximately $4.53 million.
• Several hedge funds have modified their stakes in Kura Oncology, with Ieq Capital LLC acquiring a new stake worth $646,000 during the first quarter.
• Kura Oncology reported a loss of ($0.75) earnings per share for the last quarter, significantly missing analysts' expectations.

Trexquant Investment LP grew its holdings in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 21.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 685,970 shares of the company's stock after purchasing an additional 119,025 shares during the period. Trexquant Investment LP owned about 0.79% of Kura Oncology worth $4,527,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology in the 1st quarter worth $66,000. Flower City Capital bought a new stake in shares of Kura Oncology in the 1st quarter worth $79,000. E Fund Management Co. Ltd. increased its holdings in shares of Kura Oncology by 18.9% in the 1st quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company's stock worth $81,000 after purchasing an additional 1,951 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Kura Oncology in the 4th quarter worth $99,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Kura Oncology by 117.8% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,474 shares of the company's stock worth $115,000 after purchasing an additional 9,450 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on KURA shares. Guggenheim started coverage on Kura Oncology in a report on Thursday. They issued a "neutral" rating for the company. Mizuho dropped their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, May 19th. Wall Street Zen upgraded Kura Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. JMP Securities dropped their price target on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research note on Monday, August 11th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research note on Thursday, June 26th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $24.10.

Kura Oncology Stock Performance

NASDAQ KURA traded up $0.09 on Friday, hitting $8.22. 1,304,562 shares of the company traded hands, compared to its average volume of 1,955,150. The company has a market capitalization of $713.50 million, a price-to-earnings ratio of -3.64 and a beta of 0.19. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The business's 50 day moving average price is $6.66 and its 200-day moving average price is $6.57. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $21.40.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million during the quarter, compared to the consensus estimate of $64.95 million. Equities analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.